Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Headquarters

Stage

Employees

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

VP of Manufacturing

Finance Director

Director of Legal

Director of Preclinical Development

Mohammad Razvi

Director of Clinical Operations & Development

Similar companies

GRAIL

27 followers

Pfizer

439 followers

AbbVie

149 followers

Incyte

14 followers

Adaptive Biotechnologies

11 followers

ImmunityBio

2 followers

TG Therapeutics

1 follower

Cellares

2 followers

Intercept Pharmaceuticals

1 follower

Gilead Sciences

119 followers

Harvey

2 followers

Discover companies